VivoSeq
Neurology

Neuromuscular Blockade Reversal Agent

1

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Neuromuscular Blockade Reversal Agent is an early-stage landscape with 1 program across 1 company. The most active players are Merck & Co.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

2 programs

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Sugammadex /kg

Merck & Co.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Completed1 · 33%

Clinical Trials

Trial Activity

Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children
Completed·—·Phase 4·NCT02455921·200 enrolled
A Prospective, Randomized, Double-Blind Study of the Incidence, Severity, and Risk Factors of Clenching Induced by Sugammadex During Neuromuscular Blockade Reversal
Recruiting·WWonkwang University Hospital·Preclinical·NCT06962007·240 enrolled
Comparison of the Effects of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter During the Postoperative Extubation Period
Recruiting·CCukurova University·Approved·NCT07666984·86 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)